Role of the endocannabinoid system in Alzheimer's disease: New perspectives
- 3 September 2004
- journal article
- review article
- Published by Elsevier in Life Sciences
- Vol. 75 (16), 1907-1915
- https://doi.org/10.1016/j.lfs.2004.03.026
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Neuroprotective effect of cannabidiol, a non‐psychoactive component from Cannabis sativa, on β‐amyloid‐induced toxicity in PC12 cellsJournal of Neurochemistry, 2004
- Cannabinoids and neuroinflammationBritish Journal of Pharmacology, 2004
- Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid‐type CB2 receptorBritish Journal of Pharmacology, 2003
- Anandamide and noladin ether prevent neurotoxicity of the human amyloid-β peptideNeuroscience Letters, 2002
- Inflammation in Neurodegenerative Disease—A Double-Edged SwordNeuron, 2002
- The fatty acid amide hydrolase (FAAH)Prostaglandins, Leukotrienes & Essential Fatty Acids, 2002
- Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's typeBrain Research Reviews, 2001
- Microglia and the Immune Pathology of Alzheimer DiseaseAmerican Journal of Human Genetics, 1999
- Effects of Dronabinol on anorexia and disturbed behavior in patients with Alzheimer's diseaseInternational Journal of Geriatric Psychiatry, 1997
- Molecular characterization of a peripheral receptor for cannabinoidsNature, 1993